Elisa Cimetta presented her work on microscale technologies, microfluidic culture platforms, and advanced biological models for developing and testing new drugs and therapies in SPL's Through the Looking Glass seminar series.
Florian Jug presented his work on artificial intelligence and machine learning for quantitative bioimage analysis and open microscopy software in SPL's Through the Looking Glass seminar series, beginning conversations that would grow into a productive long-term collaboration.
Congratulations to Bohdana Horda, who continues with SPL as a PhD student working on hydrogel fabrication and engineered cell-culture platforms.
Melissa Pezzotti visited the Chan Zuckerberg Biohub to assemble and test an open light-sheet microscope, bringing new volumetric-imaging capability back to SPL.
Francesco gave the invited presentation ‘Lessons learned on how (not) to build a heart’ at TERMIS-EU 2022, reflecting on the opportunities and productive failures of cardiac tissue engineering.
Alice Albini moves into a new University of Pavia role after helping SPL establish its grant and reporting operations. We thank her warmly and wish her every success in her next chapter.
Our efficient isogeometric collocation framework for cardiac electrophysiology is published, reducing computational cost while preserving the geometry and dynamics needed for heart models.
Congratulations to Moises Di Sante on his appointment as a non-tenure-track assistant professor (RTDa) at the University of Pavia, strengthening his role in SPL's stem-cell, genome-editing, and molecular-biology research.
Our book chapter reviews emerging strategies for 3D-printed tissue models and the path from fabrication technique to useful in-vitro biomedical research.
Our review of organotypic and microphysiological human tissue models is published, surveying the state of the art and the steps needed to make these systems more useful for drug discovery.
SPL has received MUR FARE support for LigHTS, an all-optical platform for engineering human tissue models at ultra-high-throughput screening scale.
SPL joins CARDIO-SCREEN to combine engineered human tissues and computational models for screening DNA- and RNA-based therapies in cardiometabolic disease.